Besides decitabine and azacytidine are DNMT inhibitors, which have won FDA approval for treating myelodysplastic syndromes, disulfiram (DSF) also acts as a DNMT inhibitor. The gene discussed is DNMT1; the disease is myelodysplastic syndrome.